Lexaria Bioscience CORP

Lexaria Bioscience Corp. is implementing a 1-for-15 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement and enhance its ability to attract business partners.

Lexaria Bioscience Corp. received a notice from Nasdaq regarding non-compliance with the $1.00 minimum bid price requirement, initiating a 180-day compliance period.

Lexaria Bioscience Corp. announced that shareholders approved all proposals at its annual meeting, including the re-election of all director nominees and the appointment of Malone Bailey LLP as auditors.

Lexaria Bioscience Corp. completed a registered direct offering and concurrent private placement, raising approximately $3.5 million for working capital and R&D.

Lexaria Bioscience Corp. secured approximately $4.0 million in gross proceeds through a registered direct offering of common stock and a concurrent private placement of warrants to fund R&D and general corporate purposes.

Lexaria Bioscience Corp. has terminated its Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC, under which it sold 14,995 shares for $38,236.

Lexaria Bioscience reports reduced operating losses and increased cash reserves, but faces ongoing concerns about continuing as a going concern.

Lexaria Bioscience Corp. reported a significant decrease in revenue for the six months ended February 28, 2026, compared to the prior year, while strengthening its cash position through equity financings.

Lexaria Bioscience Corp. reported a reduced net loss in Q1 2026, driven by lower R&D expenses and recent capital raises, while advancing its DehydraTECH drug delivery technology for GLP-1 drugs and CBD for hypertension.

Lexaria Bioscience Corp. reported a significant increase in net losses for the nine months ended May 31, 2025, driven by substantial investments in research and development, while also raising substantial doubt about its ability to continue as a going concern.

Lexaria Bioscience Corp. announces its Q2 2025 financial results and provides updates on its DehydraTECH drug delivery technology, particularly its application with GLP-1 drugs for diabetes and weight loss.

Lexaria Bioscience Corp.'s latest 10-Q filing reveals increased research and development expenditures alongside promising results from animal and human studies of their DehydraTECH technology.

Lexaria Bioscience Corp. reported a significant increase in net losses for fiscal year 2025, driven by substantial investments in DehydraTECH R&D for diabetes, weight loss, and hypertension treatments, while facing going concern doubts.

Lexaria Bioscience Corp.'s annual 10-K filing details advancements in its DehydraTECH drug delivery platform, focusing on GLP-1/GIP drugs and hypertension treatments.

Lexaria Bioscience Corp. Director Christopher Bunka gifted 100,000 common shares back to the company's treasury.

Lexaria Bioscience Corp. Director Christopher Bunka has increased his indirect beneficial ownership in the company through recent open market purchases of common shares.

Lexaria Bioscience Director William McKechnie purchased 5,000 common shares, increasing his direct ownership and signaling confidence in the company.

Lexaria Bioscience Corp.'s President and CSO, John Martin Docherty, reported a future-dated purchase of 5,376 common shares and detailed his significant stock option holdings.

Lexaria Bioscience Corp. Secretary Vanessa Carle purchased 750 common shares at $0.91 per share, increasing her direct ownership.

Lexaria Bioscience Corp.'s CEO and Director, Richard Christopher, purchased 15,000 common shares at $0.9094 per share, increasing his direct beneficial ownership to 65,000 shares.

Lexaria Bioscience Corp. announced its 2026 Annual Meeting of Shareholders to be held on January 27, 2026, to vote on director elections, auditor ratification, and director acts.

Lexaria Bioscience Corp. has scheduled its 2025 annual shareholder meeting for January 14, 2025, to vote on key proposals including the election of directors, ratification of auditors, executive compensation, and a warrant exercise proposal.

Lexaria Bioscience Corp. will hold its annual shareholder meeting on April 23, 2024, to elect directors, ratify the appointment of auditors, and approve acts of the directors.

Lexaria Bioscience Corp. filed an S-1/A registration statement for the resale of up to 2.76 million common shares by selling stockholders, with potential proceeds from warrant exercises earmarked for R&D.

Lexaria Bioscience Corp. filed an S-1 registration statement for the resale of up to 2,760,000 common shares by selling stockholders, with the company not receiving direct proceeds from these sales but potentially from warrant exercises.

Lexaria Bioscience Corp. has filed a registration statement for the resale of up to 2,917,032 shares of its common stock by a selling stockholder, which are issuable upon the exercise of a warrant issued on April 30, 2024.

Lexaria Bioscience Corp. has filed a registration statement for the resale of up to 1,612,989 shares of its common stock by selling stockholders, which are issuable upon the exercise of outstanding warrants.